SCHEMBL4883291

SCHEMBL4883291

COC(=O)c1cccc(-n2c(=O)n([C@H]3CC[C@@H](NC(=O)CC(C)C)CC3)c(=O)c3cc(F)cnc32)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
PDE4B Q07343 3/20 0.38
PDE4D Q08499 3/20 0.38
PDE4A P27815 1/20 0.38
PDE4C Q08493 1/20 0.38
TNF P01375 6/20 0.34
LITAF Q99732 6/20 0.34
MAPK8 P45983 1/20 0.34
EPHX2 P34913 1/20 0.34
GAA P10253 1/20 0.34
TTK P33981 2/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2B Q13224 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
ALDH1A1 P00352 1/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4883295 1.00 JAK2 (0.39) JAK2JAK1PDE4BPDE4DPDE4A
SCHEMBL4887195 0.91 PDE4B (0.39) PDE4BPDE4DPDE4APDE4CTNF
SCHEMBL4887192 0.91 PDE4B (0.39) PDE4BPDE4DPDE4APDE4CTNF
SCHEMBL4879150 0.90 PDE4B (0.38) JAK1PDE4BPDE4DPDE4APDE4C
SCHEMBL4879164 0.90 PDE4B (0.38) JAK1PDE4BPDE4DPDE4APDE4C
SCHEMBL4870413 0.89 PDE4B (0.40) JAK2JAK1PDE4BPDE4DPDE4A
SCHEMBL4870421 0.89 PDE4B (0.40) JAK2JAK1PDE4BPDE4DPDE4A
SCHEMBL4886119 0.88 PDE4B (0.39) PDE4BPDE4DPDE4APDE4CTNF
SCHEMBL4886115 0.88 PDE4B (0.39) PDE4BPDE4DPDE4APDE4CTNF
SCHEMBL4879091 0.87 PDE4B (0.38) PDE4BPDE4DPDE4APDE4CTNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227797-A1 Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases ASTRAZENECA AB (SE) 2008-09-18 US claimed
US-20080227797-A1 Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases ASTRAZENECA AB (SE) 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227797-A1 Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases PDE4A, PDE4B, PDE5A JAK2 807/4885JAK1 301/4885PDE4B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.